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present study, we report on the clinical and economical outcomes associated with 
omalizumab use in a cohort (n  23) of Italian adult asthmatics treated for a mean of 
10 months (range: 2–22). The pharmacoeconomic value of the treatment is assessed 
with the cost/utility ratio evaluation. RESULTS: Omalizumab signiﬁcantly improved   
asthma control and these patients’ health-related quality of life, with respect to the 
year preceding its inclusion in their therapeutic strategy. Despite reducing the costs of 
symptomatic drugs and hospital care for this patient population, the net economic 
effect of omalizumab introduction is an estimated increase of about a350 in overall 
monthly costs. However, when related to the increase in health beneﬁts, this cost 
increase results in an incremental cost/utility ratio of about a26,000/quality-adjusted 
life years gained, a favourable value according to the willingness to pay for health ben-
eﬁts in industrialised countries. CONCLUSIONS: Omalizumab therapy signiﬁcantly   
improved clinical outcomes in difﬁcult-to-treat asthmatic patients. Costs also increased, 
but this increase appears to be justiﬁed by the important clinical beneﬁts achieved.
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OBJECTIVES: It is hypothesised that the presence of ocular manifestations (Oc         Ns) 
in addition to nasal symptoms (Ns) places an additional burden on Allergic Rhinitis 
patients. This study investigated the impact on the Quality of Life (QoL) and Burden 
of Illness (BoI) among AR patients in France, Germany, Italy and Spain. METHODS: 
The data were drawn from a cross-sectional study of consulting patients undertaken 
in May/June 2008 (Adelphi). Data were collected by doctors who included records 
relating to the next consecutive 4–5 patients consulting for AR. Patients were invited 
to ﬁll out self-completion questionnaires: QoL and work productivity measures such 
as Mini-RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire), PSQI (Pittsburgh 
Sleep Quality Index) and WPAI (Work Productivity and Activity Impairment question-
naire). Propensity scoring (PS) methods were used to match the two comparison 
groups (OcNs patients vs Ns only) RESULTS: The total sample size was 750 and       
70% of these patients (526) presented with both symptoms (OcNs). The results were 
consistent in all domains of the QoL tools with OcNs patients displaying poorer 
QoL. Clinically differences were found in the overall quality of life (RQLQ) score 
(2.54 vs. 1.96, p  0.01). Regarding sleep quality (measured by the PSQI), the global 
score showed a statistically difference (5.41 vs. 4.57, p  0.05), with the OcNs group 
falling in the “poor sleepers” category (score above 5). Regular activities (36% vs. 
29%, WPAI : AS percent impairment, P  0.05) and impact on work (0.8 vs. 0.3 days, 
time off work due to AR in the last 3 months, p  0.05) also showed a higher burden 
in OcNs patients. CONCLUSIONS: AR patients with both ocular and nasal symp-       
toms have signiﬁcantly poorer QoL and quality of sleep and take more time off 
work/usual activities than those with nasal symptoms only. These patients would 
beneﬁt from therapies that are proven to speciﬁcally address ocular symptoms in 
addition to nasal symptoms.
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OBJECTIVES: It is hypothesised that the presence of ocular symptoms (Oc         Ns) in 
addition to nasal symptoms (Ns) results in additional resource utilization. This study 
investigated the impact on burden of illness (BoI) among AR patients in France, 
Germany, Italy and Spain. METHODS: The data were drawn from a cross-sectional       
study of consulting patients undertaken in May/June 2008 (Adelphi). Data were col-
lected by doctors who included records relating to the next consecutive 4–5 patients 
consulting for AR. Patients were invited to ﬁll the WPAI (Work Productivity and 
Activity Impairment) questionnaire. Propensity scoring (PS) methods were used to 
match the two comparison groups (OcNs patients vs Ns only). RESULTS: A total 
of 1009 patients meeting the inclusion criteria of which 69% (700) presented with            
both symptoms (OcNs). The OcNs patients were prescribed 15% more AR medica-
tions (e.g. inhaled nasal corticosteroids, NSAs; 1.6 vs. 1.4, p  0.05) and required 
23% more consultations with health care services concerning their AR condition (4.9 
vs. 4.0, p  0.05). Of the 1009, 750 ﬁlled in the self-completion questionnaire (includ-
ing 526 OcNs patients). All work related AR WPAI domains were statistically dif-
ferent with OcNs patients recording greater impact including proportion of work 
time (hours) missed due to AR in the last 7 days (3.3% vs. 0.7%, p  0.05), impair-
ment while working (hours worked in the last 7 days, 32.6% vs. 21.8%, p  0.05) In 
addition, OcNs patients recorded more actual days off work due to AR over the 
preceding 3 months compared with patients with nasal symptoms only (0.8 vs. 0.3 
days p  0.05). CONCLUSIONS: AR patients with both ocular and nasal symptoms        
place a signiﬁcant additional burden on resource utilisation and experience greater 
lost productivity than those with nasal symptoms only. Therapies that are proven to 
speciﬁcally address ocular in addition to nasal symptoms would result in beneﬁts from 
both the direct and indirect costs associated with AR.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To compare prescription patterns and treatment adherence to inhaled 
corticosteroids (ICS) and leukotriene-receptor antagonists (LTRA) among asthmatic 
children. METHODS: Using the Quebec (Canada) administrative health databases, 
we identiﬁed a cohort of 27,355 asthmatic children aged 5 to 15 years in whom 
monotherapy with ICS or LTRA was initiated between January 1, 1998 and August 
31, 2005. Prescription patterns were examined by the proportion of days’ supply 
prescribed (PDSP: number of days with supply prescribed from all physicians a patient 
consulted over the number of days of follow-up). Adherence to therapy was estimated 
by the proportion of prescribed days covered (PPDC: number of days’ supply dis-
pensed over the number of days’ supply prescribed during the follow-up). The mean 
PDSP and PPDC were compared between ICS and LTRA patients using t-tests. All 
analyses were stratiﬁed by the presence or the absence of an asthma exacerbation in 
the year prior to treatment initiation with ICS or LTRA. RESULTS: Among patients 
who had an asthma exacerbation, 7427 initiated ICS and 67 initiated LTRA therapy. 
Corresponding ﬁgures were 19439 and 422 among patients who did not have an 
asthma exacerbation. The mean PPDC was similar between ICS and LTRA users in 
both strata (68.0 % vs 64.7% in the exacerbation stratum and 63.9 vs 62.7 in the no 
exacerbation stratum), but the PDSP was signiﬁcantly lower among ICS users (32.8% 
vs 55.9% (p-value 0.001) in the exacerbation stratum and 34.0% vs 51.9% (p-value 
0.001) in the no exacerbation stratum). CONCLUSIONS: Asthmatic children treated 
with ICS and LTRA had similar treatment adherence to the prescribed medications, 
but ICS appeared to be more frequently prescribed as an intermittent rather than a 
daily controller therapy, resulting in lower usage of ICS.
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ADJUSTING THE NICOTINE DOSE: THE KEY TO A SUCCESSFUL, 
“TAILORED” METHOD OF QUITTING SMOKING
Taieb C
PFSA, Boulogne, France
INTRODUCTION: In a recent report, AFSSAPS (the French Health Products Safety 
Agency) discussed to what extent the dose selected constitutes an important success 
factor. OBJECTIVES: Assess the impact of quitting smoking in subjects receiving treat-
ment by nicotine patches, combined in some cases (and others not, depending on the 
practitioners’ approach) with nicotine pastilles to suck. METHODS: Each of the sub-
jects was included after they had expressed, during the spontaneous consultation, their 
desire to quit smoking. The cohort being pragmatic, no prescription advice was given, 
directly or indirectly, to the investigating doctors. The doctors were recruited by an 
independent service provider. Should the name of the products used not be cited? 
RESULTS: A total of 215 subjects were recruited by 67 general practitioners. Two            
analysis groups were organised, the ﬁrst group being treated with a transdermal device 
or skin patch (n  93) and the second with a transdermal device combined with pastilles 
(n  122). After 6 months, the rate of abstinence in the “Patch  Pastille” group was 
62.1% versus 39.7% in the “Patch only” group, the difference observed being signiﬁcant 
(p  0.008). CONCLUSIONS: This cohort, carried out in real conditions, highlights—in 
subjects wishing to quit smoking—the relevance of adjusting the dose with the help of 
pastilles. Therefore, it would appear that, for subjects quitting smoking, combining 
pastilles with a transdermal nicotine substitute is indispensable. The role of the health 
professional initiating the quitting programme is therefore of prime importance.
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Corporation, Bethesòn, MD, USA, 3United BioSource Corporation, London, UK
OBJECTIVES: To develop and validate an algorithm to report utilities from the 
EXACT for use in cost-effectiveness studies in the UK. Current methods to derive 
utilities for exacerbations of COPD tend to be insensitive and unresponsive to change, 
including the widely used EQ-5D. There is a need to develop a measure that captures 
the full exacerbation experience with precision and responsiveness. The EXACT is a 
condition-speciﬁc PRO developed to measure the frequency, severity, and resolution 
of COPD exacerbations. METHODS: The EXACT items reduced using Rasch analy-
ses. Remaining items and levels grouped to form health states. States cognitively 
debriefed using patients to ensure combined wording and structure were appropriate. 
Members of the general public interviewed to value 11 health states each (including 
best/worst states) using the time trade-off (TTO) technique from full health/dead over 
10 years, with worse than dead values possible. Analyses include regression techniques 
to develop models that best predict utilities. Models assessed by number of inconsisten-
cies in the health state utilities, adjusted R2, and mean squared errors. Selected model 
validated using two separate datasets—one to test the predictive properties and one 
to test responsiveness and construct validity. RESULTS: Five items with 3 to 5 levels 
were selected to comprise the EXACT-U. Health states debriefed with 14 patients 
experiencing an exacerbation within the last 6 months. Total of 60 health states 
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developed for valuation. TTO interviews conducted with 400 respondents who were 
on average 36 (SD 13.5) yrs old; 39.2% male, 60.8% female; 46.4% White British; 
and 19% with COPD experience (self or others). Analyses are currently underway to 
ﬁt and validate a model using the above criteria. CONCLUSIONS: The EXACT-U is 
a condition-speciﬁc preference-based measure for use in clinical trials to evaluate 
change in utility of a COPD exacerbation patient from baseline through to 
resolution.
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OBJECTIVES: To ﬁnalise and establish the scoring algorithm of the 12-item “COPD           
and activities of daily living (ADL)” questionnaire, a tool speciﬁcally developed to 
help in the detection of handicap in COPD patients and determine the handicap level, 
thus optimising COPD management in the primary care setting. METHODS: The 
“COPD and ADL” questionnaire was developed and tested with patients and clini-
cians. It was included for ﬁnalisation and validation in a multi-centre, cross-sectional, 
observational study involving 100 French lung specialists. Patients with COPD stage 
II to IV according to the GOLD classiﬁcation were included. Finalisation of the ques-
tionnaire included: assessment of the quality of completion, veriﬁcation of the unidi-
mensionnality hypothesis using principal component analysis (PCA) and Rasch 
modelling (Partial Credit Model). RESULTS: Sixty lung specialists each included at      
least one patient. Two hundred and eighty two COPD patients were included, of 
whom 272 (96%) returned the “COPD and ADL” questionnaire. The quality of 
completion was very good (91% of questionnaires with no missing data), conﬁrming 
the good acceptability of the items. In the PCA, the ﬁrst factor explained 58% of the 
total variance, conﬁrming the a priori unidimensionnality hypothesis. The items 
“Impact of COPD on sexual life” and “Overall perception of handicap due to COPD” 
were considered for deletion from the score because they had high residual values in 
the Rasch analysis. After reduction to a 10-item score, the ﬁt of the Rasch model was 
acceptable (C2  27.452; p  0.599). CONCLUSIONS: The “COPD and ADL” ques-    
tionnaire is a short instrument assessing the handicap level among COPD patients, 
speciﬁcally designed as a clinical tool to contribute to patient management. The next 
step will be the validation of this instrument, including the assessment of its relation-
ships with other measures of health impairment in COPD patients.
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GUIDELINES—THE EPAGGELIA STUDY
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OBJECTIVES: The Global Initiative for Asthma (GINA) 2006 guidelines were revised 
in order to provide a new classiﬁcation for asthma based on disease control and to 
include new treatment strategies. The aim of the current study was to describe the 
opinion of patients, treated according to GINA 2006 guidelines, regarding their 
asthma control, treatment satisfaction and quality of life (QoL). METHODS: EPAG-
GELIA was a descriptive, cross-sectional Greek study. The study population consisted 
of primary care patients with moderate/severe persistent asthma for q6 months, treated 
according to new strategies, as deﬁned by GINA 2006, for q3 months. Data were 
collected during a single visit via a structured questionnaire. Moreover, participating 
patients completed 3 PROs. SATQ (treatment satisfaction), ACQ-5 (asthma control), 
and MiniAQLQ (QoL). RESULTS: 801 patients (M/F/Missing: 353/443/5, age 49.3 
o 15.5, 65.7% smokers) were enrolled from 104 ofﬁce-based physicians. 40.2% of 
patients reported being “very highly” satisﬁed, 31.9% “highly” satisﬁed, 15.9% 
“adequately” satisﬁed and 12% “moderately” to “not satisﬁed” with their treatment. 
Mean SATQ score was 5.4 o 0.9. 52.6% of patients reported an ACQ-5 a1.0 and 
64% a score of 1.5. Mean ACQ-5 score was 1.3 o 1.1, whereas mean MiniAQLQ 
score was 5.3 o 1.1. Good compliance (no treatment interruption within the previous 
6 months) was shown in 46.1% of patients. ACQ-5, SATQ and MiniAQLQ scores 
in patients with no treatment interruption as compared with those in patients with 
any treatment interruption were 1.2 o 1.2, 5.4 o 0.2, 5.5 o 0.9 vs 1.5 o 1.1, 5.2 o 1.0, 
5.3 o 0.9, respectively. CONCLUSIONS: Primary care asthma patients treated accord-
ing to the 2006 GINA guidelines in Greece, showed a relatively satisfactory asthma 
control and presented with good QoL and treatment satisfaction. However, there is 
room for improvement regarding disease control and treatment compliance. Com-
pliant patients demonstrated relatively better asthma control, QoL and treatment 
satisfaction.
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OBJECTIVES: To assess the health-related quality of life (HRQL) impacts of Xolair® 
(omalizumab), in routine Belgian clinical practice in patients with severe allergic 
asthma naïve to omalizumab. METHODS: A prospective open-label, single arm, 
observational, multicenter study with one year follow-up was conducted. Amongst 
other study outcomes (e.g. treatment effectiveness, exacerbation rate, drug consump-
tion, medical resources used, safety, . . .), HRQL was gauged using validated generic 
and disease speciﬁc instruments, i.e. the European Quality of Life Questionnaire 5 
Dimensions (EQ-5D) and the Asthma Quality of life Questionnaire (AQLQ), respec-
tively. The EQ-5D was administered at baseline and after 1 year, the AQLQ was 
administered at baseline, after 16 weeks of treatment and after one year to mimic 
what is legally required by Belgian authorities. For the EQ-5D, the Flemish value set 
was used to calculate utility scores. Minimally important differences for the EQ-5D 
and AQLQ were previously reported as 0.074–0.120 (depending on the disease con-
sidered) and 0.5, respectively. RESULTS: For this study, 160 patients were enrolled 
from 35 study centers geographically spread over Belgium. A marked improvement in 
EQ-5D was observed following treatment with omalizumab, at one year, a mean 
increase from baseline of 15.4 units for the visual analog scale and 0.13 for the utility 
score (n  71) were reported. These results were corroborated by the AQLQ results 
which showed an improvement from baseline in the total score of 1.37 points at 16 
weeks (n  142) and 1.80 points at one year (n  100). Improvements observed for 
the 4 AQLQ subscales were also consistent. CONCLUSIONS: This observational 
study showed signiﬁcant HRQL improvements, both in the EQ-5D and AQLQ, with 
the use of omalizumab in routine practice amongst patients with severe allergic 
asthma.
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More than 400,000 people in Denmark suffers from chronic obstructive lung disease 
(COPD) with implications for their quality of life (QoL). As a chronic disease reha-
bilitation of COPD is important. Today this is the responsibility of the health care 
centres in the municipalities in cooperation with the general practitioners and hospi-
tals. OBJECTIVES: Investigate the improvement in quality of life for the COPD 
patients entering the health care centres for rehabilitation. METHODS: 22 Danish 
municipality health care centres (20% of Danish municipalities and 50% of current 
rehabilitation centres) participated in the project. Each centre had their own rehabilita-
tion strategy and included COPD patients undergoing rehabilitation in the project. 
QoL was one focus for measurement of the effect of the rehabilitation. The 15D 
instrument was chosen due to its high correlation with typical COPD symptoms, pul-
monary function and test capacity, and studies has found it sensitive in COPD. Besides 
QoL other effect indicators were 6 min. walking distance and shuttle walk, as well as 
demographic data was recorded in a database. Data was measured before and after 
rehabilitation in a longitudinal cohort design to measure change in outcome due to 
rehabilitation. RESULTS: 396 COPD patients completing rehabilitation (40% males, 
mean age of 68 years, BMI 25.8, 29% current smokers, 65% ex-smokers, and 40 
pack years of smoking) were included. Comparing pre- and post-rehabilitation the 
QALY value measured with the 15D instrument increased from 0.8 to 0.84 (p  0.01) 
having rehabilitation. This was also regarded as a clinical signiﬁcant change (0.03). 
Comparable with the improvement in quality of life both 6 min. walk and shuttle 
walk improved for the average patient comparing pre- and post-rehabilitation. CON-
CLUSIONS: The study shows that rehabilitation activities of COPD patients in the 
health care centres in Danish municipalities is important as it signiﬁcantly improves 
patients quality of life.
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ASSOCIATION BETWEEN SMOKING AND HEALTH-RELATED QUALITY 
OF LIFE
Rasch A, Greiner W
University of Bielefeld, Bielefeld, Germany
OBJECTIVES: The aim of this study was to analyse the association between tobacco            
consumption and Health-Related Quality of Life (HRQoL) in a general population 
on the basis of a representative panel dataset in Germany. METHODS: The analysis  
was designed as a cross-sectional study using the data of the “German Socio-Economic 
Panel Study” (SOEP) for the year 2006. The HRQoL was measured by the SF-12v2 
(SOEP-Version with norm-based scores for all dimensions). For each of the eight 
subscores and both composite scores a separate multivariate linear regression analysis 
